NinePoint Medical Imaging Technology Profiled in Three Recent Publications
Data Demonstrates OCT Imaging in Pulmonary Applications
NinePoint Medical, Inc., an emerging leader in the development of medical devices for in vivo imaging, today announced that data featuring its core imaging technologies were recently published in three major pulmonary journals. This research from Massachusetts General Hospital (MGH), highlighting pulmonary applications of advanced optical coherence tomography (OCT) and optical frequency domain imaging (OFDI), was featured in the American Journal of Respiratory and Critical Care Medicine, CHEST and the Journal of Visual Experiments. The technology has been licensed by NinePoint Medical from MGH and is currently in the development phase for pulmonary applications.
American Journal of Respiratory and Critical Care Medicine
The potential of utilizing OCT to improve the success of lung tumor biopsies is evaluated in the American Journal of Respiratory and Critical Care Medicine, in an article titled “Seeing Beyond the Bronchoscope to Increase the Diagnostic Yield of Bronchoscopic Biopsy”. The authors conclude that “Together, structural and polarization-sensitive OCT provide a synergistic depiction of both tissue microstructure and composition that may be useful in guiding biopsy site selection and optimizing tumor content for both diagnosis and molecular profiling.” Images from the study were also featured on the cover of the January issue.
Research published in CHEST evaluates the relationship between images derived from the technology and lung pathology. This study showed that advanced OCT, also known as OFDI, allowed distinct visualization of bronchial tissue. The paper, titled “Volumetric Optical Frequency Domain Imaging of Pulmonary Pathology With Precise Correlation to Histopathology,” was published in the January issue.
Journal of Visual Experiments
The Journal of Visual Experiments (JOVE), a peer-reviewed video journal, also highlights the OFDI technology for use in ex vivo pulmonary imaging. The video article, titled “Optical Frequency Domain Imaging of Ex Vivo Pulmonary Resection Specimens: Obtaining One to One Image to Histopathology Correlation,” was presented both in video and text in January.
“It is very exciting to see research that expands our understanding of the potential for advanced OCT, the technology underlying our NvisionVLE Imaging System, in pulmonary imaging and demonstrates the value of imaging tissue microstructure," said Charles Carignan, M.D., president and chief executive officer of NinePoint Medical. “MGH continues to be a leader in research efforts to advance the field and is a tremendous collaborator for NinePoint. We look forward to continuing our partnership with MGH in the research and development of advanced imaging techniques to improve clinical outcomes and efficiencies.”
About NinePoint Medical, Inc.
NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo imaging devices focused on dramatically improving patient care. The proprietary NvisionVLE™ Imaging System will enable physicians and pathologists, for the first time, to view real-time, high-resolution, cross-sectional images of organs and tissues up to 3mm deep at seven micron resolution. NinePoint is preparing for a commercial launch of the NvisionVLE Imaging System in the U.S. in 2013.
The FDA cleared indication for the NvisionVLE Imaging System is for use as an imaging tool in the evaluation of human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners. For more information, please visit www.ninepointmedical.com.